The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults ...

Annual injections, every-4-month dosing, and a once-monthly pill could reshape HIV prevention. Yet the faculty agree the most ...

Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank ...

Linda Bradley, MD, explains why blind endometrial sampling may miss focal uterine pathology and when persistent abnormal ...

October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart ...

Patient Care Online offers clinical news and resources for primary care clinicians, focusing on disease states, guidelines, and trends to improve care.

Pauline M. Maki, PhD, discusses how the boxed-warning removal for hormone therapy and an expanding class of neurokinin-targeted therapies broaden options, and shares her key takeaway from OPTION-VMS.

Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.

Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, ...

Sleep disturbance is often the most bothersome symptom of the menopause transition, yet it frequently goes unreported unless ...

Cheryl Cox Kinney, MD, identifies VMS red flags that warrant further evaluation, including fever, weight loss, ...